# A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years

> **NCT02269488** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 100 (actual)

## Conditions studied

- Healthy Japanese Children Age 2 Years Through 6 Years

## Interventions

- **DRUG:** MEDI3250

## Key facts

- **NCT ID:** NCT02269488
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2015-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02269488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02269488, "A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT02269488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*